tirzepatide vs glp-1 File:Tirzepatide+Semaglutide vs. GIP.svg Tirzepatide Vs. Semaglutide: Which Is

For menopausal women, these effects are usually manageable and preferable to continued metabolic decline

Some GLP-1 therapies have cardiovascular outcome evidence in specific patient populations, but patients should not stop blood pressure medications, cholesterol medications, diabetes medications, or cardiology care without medical guidance

Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes2022 A

2, 1135 (CRC Press, 2008)

NAD+ targets mitochondria, neurons, and metabolic tissue

Losing 5% to 10% of body weight through diet and exercise has been associated with a reduced risk of cardiovascular disease in adults who are obese or overweight